Cerity Partners’s Ensysce Biosciences ENSC Stock Holding History

Cerity Partners’s Portfolio ENSC Stock Details ENSC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1,428	Closed	-$5.14K	–	2475
2024 Q3	$5.14K	Buy	+1,428	New	+$8.66K	﹤0.01%	2523
2022 Q4	–	Sell	-42	Closed	-$32K	–	1499
2022 Q3	$32K	Buy	+42	New	+$68.5K	﹤0.01%	1153

Other funds holding ENSC

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Cerity Partners's ENSC Position: Q4 2024 in Review

Cerity Partners sold out of Ensysce Biosciences (ENSC) in Q4 2024, closing a stake of 1,428 shares — an estimated $5.14K sold.

Cerity Partners first reported a position in ENSC in Q3 2022 and held it in 2 quarters. The position peaked at $32K in Q3 2022. 8 funds tracked by Wall St. Rank hold ENSC as of Q4 2024.

Cerity Partners reported no remaining Ensysce Biosciences position as of Q4 2024 after selling out during the quarter.
Cerity Partners sold 1,428 Ensysce Biosciences shares in Q4 2024, an estimated $5.14K.
Cerity Partners first reported a position in Ensysce Biosciences in Q3 2022 and held it in 2 quarters.
Cerity Partners's Ensysce Biosciences position peaked at $32K in Q3 2022.
8 funds tracked by Wall St. Rank held Ensysce Biosciences as of Q4 2024.

Based on Cerity Partners's 13F filing for Q4 2024, filed 13 Feb 2025.